MedTrace Logo

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

NCT03568929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 257

Last updated 2021-11-19

No results posted yet for this study

Summary

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Conditions

  • Follicular Non-Hodgkin's Lymphoma Refractory

Interventions

DRUG

Idelalisib

Tablets administered according to the product information and treatment guidelines in routine clinical practice

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • Belgium
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568929 on ClinicalTrials.gov